Tuoxin Pharmaceutical announced on May 8pokerhandsprintable, the company's stock trading price has deviated from the closing price increase by more than 30% for three consecutive trading days. According to the relevant provisions of the "Shenzhen Stock Exchange Trading Rules", it belongs to abnormal fluctuations in stock trading.

At present, the company is actively carrying out application research on synthetic biology-related technologies in the field of nucleoside and nucleotide products. Related technologies are applied to the production of some products. In 2023, the revenue realized by such products will account for less than 5% of operating income, accounting for It is relatively low and there is greater uncertainty about future development.

(Article sourcepokerhandsprintable: Interface News)